Cholinergic Urticaria - Efficacy of Dupilumab

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 10, 2018

Primary Completion Date

February 28, 2023

Study Completion Date

February 28, 2023

Conditions
Cholinergic Urticaria
Interventions
DRUG

Dupilumab

anti-IL4-Receptor alpha

DRUG

Placebo

Placebo

Trial Locations (8)

12203

Charité-Universitätsmedizin Berlin, Berlin

35043

Universitätsklinikum Giessen und Marburg, Marburg

48149

Hautklinik Universitätsklinikum Münster, Münster

52074

Uniklinik RWTH Aachen, Aachen

55101

Hautklinik der Universitätsmedizin Mainz Clinical Research Center, Mainz

91054

Universitätsklinikum Erlangen, Erlangen

01307

Universitätsklinikum Carl Gustav Carus, Dresden

Unknown

Universitätsklinikum Schleswig-Holstein, Klinik für Dermatologie, Venerologie und Allergologie, Kiel

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

collaborator

Proinnovera GmbH

INDUSTRY

lead

Charite University, Berlin, Germany

OTHER